Patents Examined by Svetlana M Ivanova
  • Patent number: 10912762
    Abstract: The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: February 9, 2021
    Inventors: Guillaume El Glaoui, Mehdi El Glaoui, Philippe Perrin, Stéphane Droupy, Véronique Agathon-Meriau
  • Patent number: 10905665
    Abstract: Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial and viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: February 2, 2021
    Assignee: Duke University
    Inventors: Wei Chen, Robert A. Mook, Jr., Jiangbo Wang, Xiu-rong Ren, Minyong Chen, Lawrence S. Barak, Herbert Kim Lyerly, David Needham
  • Patent number: 10898502
    Abstract: A method of and composition for treating a patient having Mycobacterium avium complex (MAC), and in one embodiment Mycobacterium avium subspecies paratuberculosis (MAP), causing one or more diseases, an embodiment of the method including administering to the patient an effective amount of one or more antibiotics and administering to the patient an effective amount of ultraviolet blood irradiation (UVBI) treatments, and an embodiment of the composition including an effective amount of one or more antibiotics and an effective amount of UVBI treated blood of the patient.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: January 26, 2021
    Inventor: John Todd Kuenstner
  • Patent number: 10894055
    Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: January 19, 2021
    Assignee: AEROMICS, INC.
    Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr
  • Patent number: 10894021
    Abstract: A dietary supplement composition provided synergistic effects of xanthorrhizol and tocotrienol on malignancies. A blend of xanthorrhizol and delta tocotrienol achieved 69% growth suppression of melanoma, exceeding the sum of individual effects. In prostate cancer, 90% growth suppression was achieved by a blend of xanthorrhizol and delta tocotrienol; however, the same 90% of growth suppression was achieved by 3-fold xanthorrhizol and 1.8-fold delta tocotrienol respectively, which indicated synergistic impact of the two agents. Mechanisms of action for the anticancer property showed synergism of xanthorrhizol and tocotrienol-mediated cancer growth suppression was attributed to cell cycle arrest, at the G1 phase of cell cycle, and apoptosis. This novel dietary supplement combination of xanthorrhizol to tocotrienol (1:1 to 10:1) may provide benefits to individuals consuming it on a regular or periodic basis.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: January 19, 2021
    Inventors: Darren Heiy-Yin Chan, Chappell Rebecca Madhani, Manal Elfakhani, Sophie Thora Yount, Huanbiao Mo, Barrie Tan
  • Patent number: 10888570
    Abstract: Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: January 12, 2021
    Inventors: Anthony Pipho, Michael Paul DeHart
  • Patent number: 10874644
    Abstract: Compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, disclosed are combined therapies that modulate synapse function for treating the disease.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: December 29, 2020
    Assignee: Pharnext
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Oxana Guerassimenko, Nathalie Cholet
  • Patent number: 10869835
    Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: December 22, 2020
    Assignee: Biogen Chesapeake LLC
    Inventor: Sven Martin Jacobson
  • Patent number: 10864191
    Abstract: The present invention relates to 5-HT6 receptor antagonists for the treatment of Alzheimer's disease with comorbid apathy comprising administering an effective dose of a 5-HT6 receptor antagonist to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 15, 2020
    Assignee: H. Lundbeck A/S
    Inventor: Karl Tomas Odergren
  • Patent number: 10857127
    Abstract: The present disclosure provides pharmaceutical compositions that include one or more selective estrogen receptor modulator(s) (SERM(s), e.g., Lasofoxifene) and four or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be able to form nanodroplets (e.g., by self-nanoemulsifying) in vaginal fluid and to deliver the one or more SERM(s) to the vagina of a female subject. The pharmaceutical compositions may be useful in treating or preventing vulvovaginal atrophy, dyspareunia, sexual dysfunction, osteoporosis, or breast cancer in a female subject.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: December 8, 2020
    Assignee: Azure Biotech, Inc.
    Inventors: Valerie Ceva, Steven R. Goldstein, Susan L. Levinson, David D. Thompson, Andreas Bernkop-Schnürch, Isabelle Nardin
  • Patent number: 10849915
    Abstract: Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: December 1, 2020
    Assignee: The Johns Hopkins University
    Inventors: Barbara Slusher, Rana Rais, Xuhang Li
  • Patent number: 10851063
    Abstract: A method for producing substantially pure levorphanol and related compounds, when compared to the conventional process, is provided. In particular, a method for producing substantially pure levorphanol tartrate dihydrate is described. Also described are compositions comprising levorphanol and related compounds, particularly compositions comprising levorphanol tartrate dihydrate, levomethorphan, and norlevorphanol in which the levomethorphan and norlevorphanol are present in the composition in reduced levels.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: December 1, 2020
    Inventors: William Dubay, Alex Nichols, Wei Chen, Alec Brozell, Ajay Ryerson
  • Patent number: 10842783
    Abstract: Described are methods of treating or preventing a bacterial infection by administering an antibacterial agent comprising a ?-lactamase inhibitor and one or more carbapenem to a subject.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: November 24, 2020
    Assignee: The Johns Hopkins University
    Inventor: Gyanu Lamichhane
  • Patent number: 10835530
    Abstract: Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: November 17, 2020
    Assignee: Strongbridge Dublin Limited
    Inventor: Per Marin
  • Patent number: 10836789
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: November 17, 2020
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Valeria R. Fantin, Haiying Zhou, Minna Delarae Balbas
  • Patent number: 10828369
    Abstract: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, which composition has a surface tension of 40 dynes/cm or less and has continuing spreadability, and which composition is effective in treating a disorder of the nail or nail bed.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: November 10, 2020
    Inventors: Gareth Winckle, Gregory T. Fieldson
  • Patent number: 10821120
    Abstract: The invention pertains to the use of therapeutically effective amounts of (i) vitamin A and/or functional equivalents, (ii) vitamin D and/or functional equivalents, and (iii) at least one omega-3 PUFA, preferably DHA and/or EPA, more preferably DHA and EPA, for the manufacture of a composition or medicament for treating, reducing and/or preventing neuroinflammation and/or symptoms associated with neuroinflammation in a subject in need thereof, as well as for reducing microglia activation, and/or for treating, reducing and/or preventing symptoms associated with excessive activation of microglia; and/or for reducing the secretion of inflammatory cytokines, preferably IL-6, and/or for treating, reducing and/or preventing symptoms associated with excessive secretion of inflammatory cytokines, in a subject in need thereof.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: November 3, 2020
    Assignee: N.V. Nutricia
    Inventors: Sofia Lopes Da Silva, Ladislaus Maria Broersen, Robert Johan Joseph Hageman, Jan Maarten Verkuijl
  • Patent number: 10779529
    Abstract: Blood and platelet storage and rejuvenating compositions that include triciribine, triciribine metabolites, triciribine analogs, and mixtures of the same are disclosed. Such compositions can be useful in methods for treating (e.g., storing and rejuvenating) red blood cells and platelets.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: September 22, 2020
    Assignee: RythRx Therapeutics, LLC
    Inventor: Narayanan Surendran
  • Patent number: 10765750
    Abstract: The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: September 8, 2020
    Inventor: Yoko Endo
  • Patent number: 10751330
    Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: August 25, 2020
    Assignee: Ankh Life Sciences Limited
    Inventors: Gene H. Zaid, Thomas W. Burgoyne